Brain-derived neurotrophic factor Lipid phosphatase SHIP2 Protein kinase C Alzheimer's disease Major depression A B S T R A C T Brain-derived neurotrophic factor (BDNF), an essential factor for maintaining brain functions, has been reported to be reduced in various neurological diseases, including Alzheimer's disease and major depression. Therefore, new drugs to increase the BDNF expression need to be developed. Since phosphatidylinositol (3,4,5)-trisphosphate, a membrane signaling molecule produced by phosphoinositide 3 (PI3)-kinase in the BDNF signaling, is a candidate target of SH2 domain-containing inositol 5′ phosphatase 2 (SHIP2, a 5′-lipid phosphatase), the present study examined the effect of a SHIP2 inhibitor AS1949490 on Bdnf expression in cultured cortical neurons. BDNF increased its own mRNA levels, and AS1949490 enhanced this positive feedback regulation. The effects of BDNF in combination with AS1949490 on the Bdnf mRNA levels were blocked by inhibitors of mitogen-activated protein kinase kinase (U0126), PI3-kinase (LY294002), phospholipase Cγ (U73122), and protein kinase C (bisindolylmaleimide I), whereas the effect of BDNF alone was inhibited only by U0126. The mRNA stability assay using actinomycin D demonstrated that AS1949490 reduced degradation of the self-amplified Bdnf mRNA levels, and this effect was disappeared in the presence of bisindolylmaleimide I. These results suggest that BDNF promoted the Bdnf mRNA stabilization in a protein kinase C-dependent manner only in the presence of AS1949490, thereby enhancing Bdnf expression. Furthermore, behavioral analyses indicated that central administration of AS1949490 caused memory-improving and anti-depressant effects in passive avoidance test and forced swim test, respectively. Therefore, inhibition of SHIP2 appears to be valuable therapeutic strategy against neurological disorders associated with insufficient BDNF functions.
Introduction
Brain-derived neurotrophic factor (BDNF) plays fundamental roles in brain functions, including cognition, emotion, and learning and memory (Tanila, 2017; Hing et al., 2018) . In these processes, BDNF promotes differentiation, synaptic plasticity, and survivals of neurons (Kowiański et al., 2018) . Reduced BDNF expression was associated with various neurological disorders, including Alzheimer's disease and major depression (Mitre et al., 2017; Tanila, 2017; Hing et al., 2018) . Therefore, many pharmacological studies have sought to find novel therapeutic approach via upregulation of BDNF (Nagahara and Tuszynski, 2011; Marosi and Mattson, 2014) ; however, nothing has been succeeded enough.
Expression of BDNF is controlled at transcriptional level by activitydependent mechanisms, including depolarization-induced transcription and mRNA stabilization (Fukuchi and Tsuda, 2010; Hing et al., 2018) . BDNF upregulates its own mRNA levels, thereby forming positive feedback loop responsible for memory consolidation (Bambah-Mukku et al., 2014) . BDNF activates three signaling cascades through extracellular signal-regulated protein kinase (ERK), phosphoinositide 3 (PI3)-kinase, and phospholipase Cγ (Sasi et al., 2017; Guo et al., 2018) . BDNF-induced Bdnf mRNA expression is tightly coupled to the ERK pathway, whereas little contribution of PI3-kinase and phospholipasephospholipase Cγ) may enhance BDNF expression via positive feedback mechanism.
Phosphatidylinositol phosphates [e.g., phosphatidylinositol-4,5-bisphosphate (PI(4,5)P 2 ) and phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P 3 )] regulate multiple cellular processes at plasma membrane and nucleus, including receptor signal transduction (Schramp et al., 2012) . SHIP2 is a 5′-lipid phosphatase, and acts as a negative regulator of PI3-kinase by hydrolyzing PI(3,4,5)P 3 to PI(3,4)P 2 (Sasaoka et al., 2006; Elong Edimo et al., 2013) . Also, SHIP2 controls the nuclear PI (4,5)P 2 that locally regulates gene expression via protein kinase C (Elong Edimo et al., 2013) . We have reported that overexpression of SHIP2 impairs memory functions in mice (Soeda et al., 2010) . Moreover, a SHIP2 inhibitor AS1949490 (Suwa et al., 2010) improved spatial memory in type 2 diabetic db/db mice exhibiting increased SHIP2 levels in the brain (Soeda et al., 2010) . AS1949490 also promoted axonal regeneration after injury in cultured cortical neurons (Sekine et al., 2018) . However, functional significance of SHIP2 on BDNF functions remains unknown. Since the PI3-kinase-PI(3,4,5)P 3 and phospholipase C-PI(4,5)P 2 -protein kinase C pathways are potential targets of SHIP2, we hypothesized that SHIP2 acts as a gatekeeper of the trifurcated BDNF signaling, so that inhibition of SHIP2 can activate these pathways not usually used for Bdnf expression.
In the present study, to find new approach to amplify BDNF functions, we investigated the impact of pharmacological inhibition of SHIP2 on expression and actions of BDNF. To this end, the effects of AS1949490 on BDNF-induced Bdnf mRNA expression and cell survivals against amyloid β neurotoxicity were examined in cultured cortical neurons. Furthermore, the effects of AS1949490 on memory-and depression-related behaviors in mice were examined in vivo. The present study provides new paradigm that SHIP2 is an important pharmacotherapeutic target against neurological disorders associated with insufficient BDNF functions.
Materials and methods

Materials
AS1949490 (> 20-fold selective for SHIP2 over its homolog SHIP1) was synthesized, according to the previous study (Suwa et al., 2009 ). The purity of the compound was > 95%, based on the analysis with a JNM-A400 spectrometer (JEOL, Tokyo, Japan; 400 MHz for 1H NMR). N-[4-(4-chlorobenzyloxy)pyridin-2-yl]-2-(2,6-difluorophenyl)-acetamide (CPDA) was synthesized as described previously (Ichihara et al., 2013) . Actinomycin D, LY294002, KN-93, and KT5720 were purchased from Wako Pure Chemical (Osaka, Japan). GSK2334470 was purchased from Sigma-Aldrich Japan (Tokyo, Japan). U0126 and U73122 were purchased from Abcam (Cambridge, MA, USA). Bisindolylmaleimide I was purchased from Calbiochem (San Diego, CA, USA). Amyloid β 25-35 (Aβ 25-35 ) was purchased from Bachem (Bubendorf, Switzerland). Gö6983 was purchased from Cayman Chemical (Ann Arbor, MI, USA). MK2206 was purchased from ChemScene (Monmouth Junction, NJ, USA). VO-OHpic was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All the above drugs were dissolved in dimethyl sulfoxide (DMSO). 3α-aminocholestane (3AC, Calbiochem) was dissolved in ethanol. Recombinant human BDNF was provided by Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Japan), and diluted with water containing bovine serum albumin (BSA). As vehicle control of 1 and 10 ng/ml BDNF solution, 0.005% and 0.01% BSA solution were used, respectively. Other materials were purchased from Sigma-Aldrich Japan or Wako, unless otherwise indicated.
Animals
Pregnant female Sprague-Dawley rats were purchased from Japan SLC (Shizuoka, Japan). Mice were maintained at 24 ± 1°C under specific-pathogen-free condition with daily 12-h light/12-h dark cycle.
Male C57BL/6J mice (Japan SLC) were fed a normal chow diet (PicoLab Rodent Diet 20, #5053, PMI Nutrition International, St. Louis, MO). A type 2 diabetic mouse model was prepared according to a previous study (Jiang et al., 2012) , as follows: male ICR mice (8 weeks old, Japan SLC) were fed a high-fat diet (HFD, 60 kcal% fat, D12492, Research Diets Inc., New Brunswick, NJ) for 4 weeks, applied a bolus intraperitoneal (i.p.) injection of streptozotocin (STZ, 100 mg/kg), and maintained for 4 additional weeks. Glucose tolerance test (2 g glucose/ kg, i.p.) was conducted 1 week after behavioral tests (see below) to confirm impairment of glucose metabolism in the diabetic mice (referred to as HFD/STZ mice). Impaired glucose tolerance was defined as peak blood glucose levels above 400 mg/dl after the glucose loading (nine of 45 mice were excluded from Y-maze test and nine of 43 mice were excluded from passive avoidance test due to insufficient glucose elevation). Glucose levels in blood samples from the tail vein were measured by a glucometer (Accu-Chek Aviva Nano, F. Hoffmann-La Roche Ltd., Basel, Switzerland). Experimental procedures used in this study were approved by the Committee of Animal Experiments at University of Toyama.
Primary culture of rat cerebral cortical neurons
Cell culture was performed, according to the protocols described previously (Tsuneki et al., 2017) with slight modifications. In brief, brains were isolated from E17-18 embryos from pregnant SpragueDawley rats. The cortical tissues from 5 to 7 embryos in the same dissection were pooled. The tissues were dispersed in Dulbecco's Modified Eagle's Medium (DMEM; Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (FBS, 172012, Nichirei Biosciences, Sigma-Aldrich Japan), NaHCO 3 (1.5 g/L), D-glucose (3.5 g/L), and kanamycin sulfate (100 μg/ml). The cortical cells were obtained using trypsin (TrypLE Express, Gibco), 0.004% DNase I, and 0.03% trypsin inhibitor. Cells were seeded at 2.0 × 10 6 cells/well in 6-well plates, 1.0 × 10 6 cells/well in 12-well plates, or 5.0 × 10 5 cells/well in 24-well plates which were coated with poly-D-lysine (5 μg/ml). Cortical cells were cultured in 10% FBS-containing DMEM at 37°C with 10% CO 2 for 3 days, and then treated with cytosine arabinoside (Ara-C, 10 μM) for 24 h to suppress the growth of glial cells. In this study, the cultured cells obtained without the Ara-C treatment are referred to as cortical cells, and the surviving cells after the treatment with Ara-C on day 4 are referred to as cortical neurons. Experiments were repeated at least three times, unless otherwise indicated.
RT-PCR analysis
The cortical neurons/cells were cultured in serum-free DMEM in 6-well plates. On day 6-7 in culture, cells were treated with several signal transducer inhibitors, AS1949490, and BDNF for indicated times, in order to examine the drug effects on the mRNA expression of neurotrophic factors, containing Bdnf, neurotrophin-3 (Ntf3), and nerve growth factor (Ngf). Extraction of total RNA and reverse transcription were performed as described previously (Tsuneki et al., 2017) . Quantitative PCR was conducted with a real-time PCR system (Mx3000p, Stratagene, La Jolla, CA, USA) using the following protocols: initial denaturation (95°C for 10 s), PCR cycles (37 for Bdnf, NTf3, and Ngf, and 30 for Gapdh), denaturation (95°C for 10 s), annealing (Bdnf and Ntf3: 57°C for 45 s, Ngf: 62°C for 45 s, Gapdh: 55°C for 45 s), and elongation (72°C for 60 s). The primer pairs used in this study were as follows; Bdnf exon IV-IX: 5′-TCGGCCACCAAAGACTCG-3′, 5′-GCCCAT TCACGCTCTCCA-3′;
Ngf: 5′-CCAAGCACTGGAACTCATACTGC-3′, 5′-CTGCTGAGCACACACACGCAG-3′; Ntf3: 5′-CTTATCTCCGTGGCATC CAAGG-3′, 5′-TCTGAAGTCAGTGCTCGGACGT-3′; Gapdh: 5′-TCCATGA CAACTTTGGCATCGTGG-3′, 5′-GTTGCTGTTGAAGTCACAGGAGAC-3′; and β-actin: 5′-TTTGAGACCTTCAACACCCC-3′, 5′-ACGATTTCCCTCTC AGCTGT-3′. The mRNA level of the neurotrophic factor was normalized to the Gapdh mRNA level in each sample, unless otherwise indicated. In the mRNA stability assay, cultured neurons in 12-well plates were pretreated with bisindolylmaleimide I for 30 min, and AS1949490 was added for 1 h, and then BDNF was further added for 1 h. Actinomycin D (10 μg/ml) was finally added for indicated times, and subjected to RT-PCR analysis.
Western blot analysis
The cortical neurons/cells were cultured in serum-free DMEM in 6-well plates. On day 6-7 in culture, cells were treated with signal transducer inhibitors, AS1949490, and BDNF for indicated times and subjected to Western blot analysis as described previously (Tsuneki et al., 2017) with slight modifications. In brief, cells were lysed in a lysis buffer [20 mM Tris (pH 7.4), 5 mM ethylene diamine tetra-acetic acid (EDTA, pH 8.0), 10 mM Na 4 P 2 O 7 , 100 mM sodium fluoride, 1% Triton X-100, 10 μg/ml aprotinin, 10 μg/ml leupetin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM Na 3 VO 4 ]. The lysates were mixed with Laemmli buffer containing ( ± )-dithiothreitol, and boiled proteins were separated by SDS-PAGE, and transferred to polyvinylidene difluoride membrane (EMD Millipore, Billerica MA, USA). After treatment with a blocking buffer (50 mM Tris, 150 mM NaCl, 0.1% tween 20, 5% nonfat milk, pH 7.5), the membranes were incubated overnight at 4°C with primary antibodies, as follows: anti-Akt (B-1) antibody (sc-5298, 1:200, Santa Cruz Biotechnology), antiphospho-Akt (Ser473) antibody (9271, 1:1000, Cell Signaling Technology, Denver, MA, USA), anti-CREB (48H2) antibody (9197, 1:1000, Cell Signaling Technology), anti-phospho-CREB (Ser133) (D1G6) antibody (4276, 1:1000, Cell Signaling Technology), anti-p44/42 mitogenactivated protein kinase (MAPK) (ERK1/2) antibody (9102, 1:1000, Cell Signaling Technology), anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (9101, 1:1000, Cell Signaling Technology), anti-phosphatase and tensin homolog deleted on chromosome 10 (PTEN) antibody (sc-7974, 1:1000, Santa Cruz Biotechnology), antiprotein tyrosine phosphatase 1B (PTP1B) antibody (PH01-100UGCN, 1:1000, Merck Millipore), anti-SHIP2 antibody (1:2000, prepared as described previously by Ishihara et al., 1999) , anti-SHIP1 antibody (sc-8425, 1:200, Santa Cruz Biotechnology), anti-β-actin antibody (3700, 1:5000, Cell Signaling Technology), and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (AB2302, 1:300, Merck Millipore). Subsequently, the membranes were incubated with secondary antibody (horseradish peroxidase-conjugated anti-mouse or rabbit IgG, GE Healthcare, Buckinghamshire, UK; diluted with Can Get Signal Immunoreaction Enhancer Solution, Toyobo, Osaka, Japan), and treated with Chemi Lumi One L (Nacalai tesque, Kyoto, Japan). The chemiluminescence was analyzed using LAS4000 (Fuji film, Tokyo, Japan). The phosphorylation levels of ERK, Akt, and CREB were normalized to total expression levels of respective proteins in each sample by using Image J software (National Institutes of Health, Bethesda, MD).
Cell viability assay
Cortical neurons/cells were cultured in 10% FBS-containing DMEM in 24-well plates. On day 7, cells were serum-starved for 24 h. On day 8, the cells were treated with AS1949490 (10 μM) for indicated times, and BDNF (1 ng/ml) was added for 3 h. Then, the cells were exposed to Aβ 25-35 for 3 h, and subjected to cell viability assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT). In this assay, cells were treated with MTT (0.25 mg/ml) for 1 h at 37°C, and washed with phosphate-buffered saline (PBS). The MTT formazan product was dissolved in DMSO. Absorbance was measured at 540 nm using a microplate reader (FilterMax F5, Molecular Devices, CA) as an index of viable cells.
Immunocytochemical analysis
Cortical neurons were cultured on coverslips coated with 0.05 mg/ ml poly-D-lysine for indicated days, and fixed with 4% paraformaldehyde/4% sucrose-containing PBS for 20 min at 25°C. After washing with PBS, cell membranes were permeabilized with 0.1% Triton X-100 for 5 min at 25°C. After washing with PBS, the specimens were treated with a blocking solution (Protein Block Serum-Free, X0909, Dako, Carpinteria, CA, USA) for 30 min. After washing with PBS, they were treated with primary antibody solution containing 0.1% Triton-X-100, normal goat serum (143-06561, 1:100, Wako), rabbit anti-INPPL1 (SHIP2) antibody (ab70267, 1:200, Abcam), mouse anti-microtubuleassociated protein 2 (MAP2) antibody (MAB3418, 1:200, Merck Millipore, Bedford, MA, USA), and rat anti-glial fibrillary acidic protein (GFAP) antibody (13-0300, 1:500, Invitrogen, Life Technologies) at 4°C overnight for immunolabelling of SHIP2-MAP2-GFAP proteins. Subsequently, the specimens were treated with secondary antibody solution containing 0.1% Triton-X-100, Alexa 488 goat anti-rabbit IgG antibody (A11034, 1:500, Life Technologies, Carlsbad, CA, USA), Alexa 568 goat anti-mouse IgG antibody (A11031, 1:500, Life technologies), and Alexa 633 goat anti-rat IgG antibody (A21094, 1:500, Life technologies) for 30 min at 25°C. After washing with PBS, the slides were mounted with SlowFade Gold antifade reagent with DAPI (S36939, Invitrogen). Fluorescent images were obtained using a laser scanning confocal microscope (LSM-700, Carl Zeiss, Oberkochen, Germany).
Intracerebroventricular administration
Intracerebroventricular (i.c.v.) injection of drugs was performed, according to the previous report (Tsuneki et al., 2017) with slight modifications. In brief, a 10-mm long guide cannula was implanted into the lateral ventricle of C57BL/6J mice (0.3 mm posterior to bregma, 0.9 mm lateral from the central suture) and HFD/STZ-ICR mice (0.6 mm posterior to bregma, 1.6 mm lateral from the central suture) on a stereotaxic frame (SR-6, Narishige, Tokyo, Japan) under anesthesia. After 5-7 days of recovery period, 2 μl of either vehicle (DMSO), AS1949490 (0.03 μmol dissolved in 2 μl DMSO), or CPDA (0.03 μmol dissolved in 2 μl DMSO) was i.c.v. injected. The injection depths were 2.2 and 3.0 mm from skull surface in C57BL/6J and ICR mice, respectively.
Mouse behavioral tests
To examine the effects of AS1949490 and CPDA on memory functions in C57BL/6J (10-11 weeks old) and HFD/STZ mice (16 weeks old), Y-maze and step-through passive avoidance tests were performed as described previously (Soeda et al., 2010; Tsuneki et al., 2017) . In the case of HFD/STZ mice, same animals were used in both memory tests conducted for three consecutive days. The SHIP2 inhibitor was i.c.v. injected 1 h before the Y-maze test.
Step-through passive avoidance test consisted of control session on day 1 and memory test session on day 2. On day 1, C57BL/6J and HFD/STZ mice received a mild foot shock (0.05 and 0.1 mA, respectively) for 2 s when they moved from the light into dark room in a passive avoidance apparatus (MPB-M001, Melquest, Toyama, Japan). The SHIP2 inhibitor was injected immediately after the control session. On day 2 (i.e., 24 h later), the latency to enter the dark room in the same apparatus was measured to evaluate memory functions.
Elevated-plus maze test and forced swim test were performed to analyze anxiety-and depressive-related behavior, respectively, in C57BL/6J mice (7-8 months old). These tests were performed according to the methods described previously (Tsuneki et al., 2016) . In brief, the drugs were i.c.v. injected once a day for 5 days. On day 1, elevated-plus maze test was conducted 1 h after the i.c.v. injection. Reduced time spent in open arm during the 5-min observation period was measured as an index of anxiety. The forced swim test was performed on day 4 and 5. A 15-min pretest in a swimming pool was carried out 1 h after the drug injection on day 4, and the 6-min forced swim test was conducted 1 h after the final drug injection on day 5. Immobilization time was measured as an index of depressive-like behavior.
Statistical analysis
Data were expressed as the means ± S.E.M. The statistical significance of differences between two groups were analyzed by Student's t-test, and statistical differences among more than three groups were examined by one-way analysis of variance (ANOVA) with Bonferroni's test using Statview software (SAS Institute, Cary, NC, USA). The P values less than 0.05 were considered statistical significant.
Results
Expression of SHIP2 in rat cerebral cortical neurons
Immunocytochemical analyses in cultured cells from rat cerebral cortex demonstrated that SHIP2 protein-like immunoreactivities (LI) were distributed in cells expressing MAP2, a neuronal dendritic marker, whereas few SHIP2-LI were detected in cells expressing GFAP, an astrocyte marker, on day 5 and 10 ( Supplementary Fig. 1 ). These results indicate that SHIP2 was preferentially expressed in neurons rather than astrocytes, and it was distributed in both the cell soma and dendrites of neurons. Similar immunostainings were obtained in three separate experiments (data not shown). More prolonged culture caused apparent growth of astrocytes, despite treatment with Ara-C on day 4 (data not shown). Western blot analyses demonstrated that the protein levels of SHIP2, PTEN, and PTP1B were constant on day 5 and 10 in cultured cortical neurons prepared with Ara-C treatment (Supplementary Fig. 2A ) and on day 4 and 7 in cultured cortical cells without Ara-C treatment ( Supplementary Fig. 2B ). More prolonged culture caused increase in the SHIP2 levels and decrease in the PTEN levels (Supplementary Fig. 2A and B) along neuronal development (Fukuchi et al., 2014) . The PTP1B levels were relatively stable, compared to these two lipid phosphatases. Similar results were obtained in two separate experiments (data not shown). Therefore, the cortical neurons/ cells cultured for less than 10 days were used in the following experiments because of the constant levels of phosphatases, including SHIP2.
SHIP1, a homolog of SHIP2, is known to be predominantly expressed in hematopoietic cells (Fernandes et al., 2013) . In fact, large amounts of SHIP1 protein were detected in the spleen of mice, whereas no expression of SHIP1 was detected in the hippocampus, cerebral cortex, hypothalamus, and skeletal muscle ( Supplementary Fig. 3A) . Also, in cultured rat cortical neurons, the expression of SHIP1 protein was negligible. In contrast, SHIP2 protein was apparently expressed in the mouse hippocampus, cerebral cortex, hypothalamus, and skeletal muscle and in cultured rat cortical neurons.
Effect of AS1949490 on BDNF mRNA expression
The expression levels of Bdnf exon IV-IX mRNA were increased by a SHIP2 inhibitor AS1949490 (1-30 μM, Suwa et al., 2009 ) in a concentration-dependent manner in cultured cortical neurons (Fig. 1A) . The increasing effect at 30 μM reached significant levels. In cortical cells, BDNF (1 ng/ml, 3 h) increased the levels of Bdnf exon IV-IX mRNA, and the increasing effect of BDNF was enhanced by 10 μM AS1949490 (Fig. 1B) . The Ntf3 mRNA levels were not affected by AS1949490 and BDNF (Fig. 1C) . The Ngf mRNA levels were increased by 10 μM AS1949490 alone or 1 ng/ml BDNF alone, but no synergistic increase by AS1949490 and BDNF was observed (Fig. 1D) . Thus, AS1949490 specifically enhanced BDNF-induced Bdnf mRNA expression. In contrast, VO-OHpic (5-500 nM, a PTEN inhibitor, Rosivatz et al., 2006) reduced basal Bdnf mRNA levels in a concentration-dependent manner in cortical neurons (Fig. 1E) . Moreover, VO-OHpic (0.5 nM) failed to enhance BDNF-induced upregulation of Bdnf mRNA (Fig. 1F) . 3AC (10 μM, a SHIP1 inhibitor, Brooks et al., 2010) did not enhance BDNF-induced Bdnf mRNA expression ( Supplementary  Fig. 3B ). These results highlight the benefit of SHIP2 inhibitor for increasing BDNF expression.
We have previously reported that BDNF induces biphasic expression of Bdnf exon IV-IX mRNA, which became overt 1-3 h (primary induction) and 24-72 h (delayed induction) during the stimuli (Yasuda et al., 2007) . Again, we detected increased levels of Bdnf mRNA after 3 h (Supplementary Fig. 4A ) and 24 h (Supplementary Fig. 4B ) of treatment with BDNF (100 ng/ml). AS1949490 (10 μM) alone elevated the basal levels of Bdnf mRNA at 24-h time point. Moreover, AS1949490 (10 μM) enhanced the BDNF (100 ng/ml)-induced Bdnf mRNA expression at both time points ( Supplementary Fig. 4A and B) .
To reveal the mechanism underlying the enhanced self-amplification of BDNF by AS1949490, the BDNF-signaling pathways responsible for increased expression of Bdnf exon IV-IX mRNA in the absence and presence of AS1949490 were compared in cultured cortical neurons. In the absence of AS1949490, the increasing effect of BDNF (10 ng/ml) on the Bdnf mRNA expression was suppressed by U0126 [10 μM, a MAPK/ ERK kinase (MEK) inhibitor, Favata et al. (1998)] (Fig. 2A) , whereas it was not affected by LY294002 (20 μM, a PI3-kinase inhibitor, Vlahos et al., 1994) (Fig. 2A) , and bisindolylmaleimide I (5 μM, a protein kinase C inhibitor, Gekeler et al., 1996) (Fig. 2B ). Gö6983 (5 μM, another protein kinase C inhibitor, Gschwendt et al., 1996) showed a decrease trend; however, the effect was not significant (Fig. 2C ). U73122 (4 μM, a phospholipase Cγ inhibitor, Burgdorf et al., 2010) did not alter the effect of BDNF alone (Fig. 2D) . On the other hand, in the presence of AS1949490 (10 μM), the increasing effect of BDNF (1 ng/ml) on the Bdnf expression was significantly enhanced (Fig. 2E-H) , as observed in Ara-C-untreated cortical cells (Fig. 1B) . The combined effects of AS1949490 (10 μM) and BDNF (1 ng/ml) were suppressed by U0126 (10 μM) and LY294002 (20 μM) (Fig. 2E ), but not affected by MK2206 (5 μM, an Akt inhibitor, Hirai et al., 2010) and GSK2334470 [5 μM, a phosphoinositide-dependent protein kinase 1 (PDK1) inhibitor, Najafov et al. (2011)] (Fig. 2F) . Surprisingly, U73122 (4 μM), Gö6983 (5 μM), and bisindolylmaleimide I (5 μM) suppressed the combined effects of AS1949490 and BDNF ( Fig. 2G and H Abraham et al., 1994 ) had no effect under this condition (Fig. 2H) . These results indicate that the MEK-ERK pathway plays fundamental role in BDNFinduced Bdnf expression, and additional contributions of PI3-kinase, phospholipase Cγ, and protein kinase C occurred only in the presence of AS1949490. Phosphorylated CREB is one of the major transcription factors for Bdnf expression (Hing et al., 2018) . To clarify which signaling pathways are involved in the phosphorylation of CREB in the absence and presence of AS1949490, the effects of the signaling inhibitors were examined in cultured cortical neurons by Western blotting. BDNF alone caused increase in the phosphorylation of ERK1/2, Akt, and CREB ( Fig. 3A-C) . Among LY294002 (20 μM), U0126 (10 μM), bisindolylmaleimide I (5 μM), and KN-93 (10 μM), only U0126 was effective to reduce the phosphorylation levels of ERK (Fig. 3A) and CREB (Fig. 3C) , whereas only LY294002 effectively reduced those of Akt (Fig. 3B) . AS1949490 (10 μM) did not enhance BDNF-induced phosphorylation of ERK1/2, Akt, and CREB ( Fig. 3D-F) . In the presence of AS1949490, U0126 (10 μM) suppressed the phosphorylation levels of ERK and CREB by BDNF without affecting those of Akt. Bisindolylmaleimide I (5 μM) had no effect under this condition (Fig. 3D-F) . These results demonstrate that BDNF-induced phosphorylation of CREB was mediated by the MEK-ERK pathway, whereas neither PI3-kinase, phospholipase Cγ, nor protein kinase C contributed to this process even in the presence of AS1949490.
To elucidate the protein kinase C-dependent mechanism by which AS1949490 and BDNF synergistically increased Bdnf mRNA, the mRNA stability assays were conducted in cortical neurons. After addition of actinomycin D (10 μg/ml) to inhibit gene transcription (Fukuchi and Tsuda, 2010) , the Bdnf exon IV-IX mRNA levels gradually decreased due to time-dependent degradation (Fig. 4A) . The remaining mRNA levels were not different between cells stimulated with or without BDNF (1 ng/ml), indicating that BDNF per se did not affect the Bdnf mRNA stability (Fig. 4A) . This notion was consistent with the previous study (Zheng and Wang, 2009) . When the remaining Bdnf mRNA levels were compared between cells stimulated with BDNF (1 ng/ml) alone or with AS1949490 (10 μM) plus BDNF (1 ng/ml), significantly higher Bdnf mRNA levels were observed in cells treated with AS1949490 plus BDNF (Fig. 4B) . Pretreatment with bisindolylmaleimide I (5 μM) suppressed the combined effects of AS1949490 plus BDNF, although bisindolylmaleimide I did not affect the Bdnf mRNA levels in cells treated with BDNF alone (Fig. 4B) . These results indicate that AS1949490 increased the stability of Bdnf mRNA in a protein kinase C-dependent manner.
Protective effect of AS1949490 against the Aβ neurotoxicity
Next, we investigated whether AS1949490 affects the protective effect of BDNF against Aβ-induced neuronal cell death. When cultured cortical neurons were exposed to Aβ 25-35 (10 μM, Zhao et al., 2018) , survival rate was markedly reduced (Fig. 5A) . Pretreatment with AS1949490 (10 μM) significantly increased cell viability in the presence of Aβ 25-35 , although BDNF (1 ng/ml) had no effect. The protective efficacy of AS1949490 alone was nearly identical to that of AS1949490 plus BDNF. Similarly, when cultured cortical cells (i.e., cells prepared without Ara-C) were exposed to Aβ 25-35 (25 μM), marked cell death was detected (Fig. 5B) . Pretreatment with 10 μM AS1949490 (Fig. 5B) and 
. Effects of AS1949490 and BDNF on the expression levels of neurotrophic factors in cultured rat cerebral cortical neurons/cells. A-F) Cells were prepared with (A, E-F) or without Ara-C treatment on day 4 (B-D). A) Effect of AS1949490 (a SHIP2 inhibitor) alone on the
Bdnf exon IV-IX mRNA levels. Cells were treated with AS1949490 (AS, 1-30 μM) for 3 h, and subjected to RT-PCR analysis. n = 8 from 4 independent experiments. B-D) Effects of AS1949490 and BDNF on the levels of Bdnf exon IV-IX (B), Ntf3 (C), and Ngf mRNAs (D). Cells were treated with AS1949490 (0 or 10 μM) for 15 min, and then BDNF (0 or 1 ng/ ml) was added for 3 h. n = 6 from 3 independent experiments in (B), and n = 5 from single experiment (C-D). E) Effect of VO-OHpic (a PTEN inhibitor) alone on the Bdnf exon IV-IX mRNA levels. Cells were treated with VOOHpic (VO, 5-500 nM) for 3 h. n = 7-8 from 4 independent experiments. F) Effects of VOOHpic and BDNF on the levels of Bdnf exon IV-IX mRNAs. Cells were treated with VO-OHpic (0 or 0.5 nM) for 1 h, and then BDNF (0 or 1 ng/ml) was added for 3 h. n = 4 from 2 independent experiments. DMSO (A-D: 0.1%, E-F: 0.05%) was used as vehicle control. Data were expressed as the mean ± S.E.M. ‡ P < 0.1, * P < 0.05, ** P < 0.01.
higher concentration (10 ng/ml) of BDNF (data not shown) protected the Aβ toxicity, although 1 ng/ml BDNF had no effect. The potency of the effect of AS1949490 alone was not different from that of AS1949490 plus BDNF. These results indicate that AS1949490 directly caused neuroprotection against the Aβ toxicity.
Effect of AS1949490 on memory, anxiety, and depression-related behaviors in mice
Finally, we performed behavioral analyses to examine the in vivo effect of AS1949490 and CPDA, a SHIP2 inhibitor structurally related to AS1949490 (Ichihara et al., 2013) . Diabetic HFD/STZ mice as well as normal C57BL/6J mice were used in memory tests, since similar type 2 diabetic model mice exhibited reduced BDNF expression and impaired learning and memory (Jiang et al., 2012; Ling et al., 2018) . In Y-maze test for evaluating short-term working memory, AS1949490 (0.03 μmol, i.c.v.) slightly, and CPDA (0.03 μmol, i.c.v.) significantly improved the performance in C57BL/6J mice (Fig. 6A) , although neither drugs were effective in HFD/STZ mice (Fig. 6B). Step-through passive avoidance test demonstrated that memory retention of the task was not affected by vehicle treatment, but slightly improved by 0.03 μmol AS1949490 (P < 0.05 between day 1 and 2 by Student's t- Fig. 2 . Effects of the signal transduction inhibitors on BDNF-induced Bdnf mRNA expression in the presence or absence of AS1949490 in cultured rat cerebral cortical neurons. Cells were treated with Ara-C on day 4. A-D) Effects of LY294002 (LY, a PI3-kinase inhibitor, 20 μM; A), U0126 (a MEK/ERK inhibitor, 10 μM; A), bisindolylmaleimide I (BIM, a protein kinase C inhibitor, 5 μM; B), Gö6983 (Gö, a protein kinase C inhibitor, 5 μM; C), and U73122 (U731, a phospholipase Cγ inhibitor, 4 μM; D) on BDNF alone-induced increase in the Bdnf mRNA levels. Cells were pretreated with the signaling inhibitors for 30 min, and then BDNF (0 or 10 ng/ml) was added for 3 h. DMSO (0.05%) was used as vehicle control. The mRNA levels were analyzed by RT-PCR. n = 8 from 4 independent experiments in A and C, n = 6 from 3 independent experiments in B, and n = 10 from 5 independent experiments in D. E-H) Effects of U0126 (10 μM; E), LY294002 (20 μM; E), MK2206 (MK, an Akt inhibitor, 5 μM; F), GSK2334470 (GSK, a PDK1 inhibitor, 5 μM; F), U73122 (4 μM; G), Gö6983 (5 μM; G), bisindolylmaleimide I (5 μM; H), KN-93 (KN, a CaMKII inhibitor, 10 μM; H), and KT5720 (KT, a protein kinase A inhibitor, 2 μM; H) on BDNF-induced increase in the Bdnf mRNA levels in the presence of AS1949490. After 30 min of treatment with the signaling inhibitors, AS1949490 (AS, 0 or 10 μM) was added for 1 h, and then BDNF (0 or 1 ng/ml) was further added for 3 h. DMSO (0.1%) was used as vehicle control. n = 8 from 4 independent experiments in E-F, and n = 6 from 3 independent experiments in G-H. Data were expressed as the mean ± S.E.M. * P < 0.05, ** P < 0.01. test) and significantly improved by 0.03 μmol CPDA in C57BL/6J mice (Fig. 6C) . In HFD/STZ mice, both AS1949490 (0.03 μmol, i.c.v.) and CPDA (0.03 μmol, i.c.v.) significantly improved passive avoidance memory on day 2 (Fig. 6D) . In elevated-plus maze test to analyze anxiety-like behavior, AS1949490 (0.03 μmol, i.c.v.) did not alter time spent in open arms (Fig. 6E ) and the number of entries into open or closed arms (data not shown) in C57BL/6J mice. In forced swim test where BDNF expression is reported to be decreased in rodent (Hing et al., 2018) , AS1949490 (0.03 μmol, i.c.v., once a day for 5 days) significantly reduced immobility time, an index of depression-like behavior, in C57BL/6J mice. Thus, AS1949490 was able to cause the memory-improving and anti-depressant effects in mice.
Discussion
In the present study, we found a new pharmacological approach to increase the BDNF expression by targeting 5′-lipid phosphatase SHIP2 in cultured cerebral cortical neurons. The increasing effect of the SHIP2 inhibitor AS1949490 on BDNF-induced Bdnf mRNA expression was mainly due to the stabilization of Bdnf mRNA in a protein kinase Cdependent but Akt-independent manner. This is an overlooked mechanism, and may be specific for BDNF signaling, because previous studies focusing on insulin signaling have demonstrated that inhibition of SHIP2 amplified the canonical PI3-kinase-Akt signaling pathway (Sasaoka et al., 2006) . Moreover, our in vivo study demonstrated that AS1949490 exerted the memory-improving and anti-depressant effects. At present, there are numerous technological limitations in central administration of BDNF to humans (Tanila, 2017) . Therefore, antagonists/blockers, such as SHIP2 inhibitors, that could disinhibit the negative regulations (Sekine et al., 2018) , are considered to be ideal pharmacological tool to enhance the BDNF functions.
The major finding of the present study is that AS1949490 enhanced BDNF-induced increase in Bdnf exon IV-IX mRNA in rat cortical neurons. The Bdnf gene has nine exons in rodents, and leads to production of different Bdnf mRNA isoforms composed of a pair of exon IX encoding for prepro-BDNF peptide and one of the others encoding for 5′-untraslated regions (Hing et al., 2018) . Among these isoforms, expression of the exon IV-IX isoform has been intensively studied because of Fig. 3 . Involvement of the MEK/ERK pathway in BDNF-induced phosphorylation of CREB in the presence and absence of AS1949490 in cultured rat cerebral cortical neurons. Cells were treated with Ara-C on day 4. A-C) Effects of LY294002 (LY, a PI3-kinase inhibitor, 20 μM), U0126 (a MEK/ERK inhibitor, 10 μM), bisindolylmaleimide I (BIM, a protein kinase C inhibitor, 5 μM), and KN-93 (KN, a CaMKII inhibitor, 10 μM) on BDNF alone-induced phosphorylation of ERK (A), Akt (B), and CREB (C). Cells were pretreated with the signaling inhibitors for 30 min, and then BDNF (0 or 10 ng/ml) was added for 30 min. D-F) Effects of bisindolylmaleimide I (5 μM) and U0126 (10 μM) on BDNF-induced phosphorylation of ERK (D), Akt (E), and CREB (F) in the presence of AS1949490. After 30 min of treatment with the signaling inhibitors, AS1949490 (AS, 0 or 10 μM) was added for 15 min, and then BDNF (0 or 1 ng/ml) was further added for 30 min. Total and phosphorylated protein levels were analyzed by Western blotting. n = 4 from 4 independent experiments. Values indicate relative phosphorylation levels of respective proteins. Data were expressed as the mean ± S.E.M. † P < 0.05, † † P < 0.01 vs.
vehicle control (0.05% DMSO). its physiologically-significant characteristics, i.e., activity-dependent and/or self-induced transcription locally at cell soma (Tuvikene et al., 2016; Hing et al., 2018) . These transcriptional regulations are reported to exhibit biphasic temporal patterns (Yasuda et al., 2007; Nakajima et al., 2015) . Based on these profiles, we examined the effects of AS1949490 mainly on the early phase peaked at 1-3 h after the induction by BDNF, rather than the late phase (> 24 h after the induction) possibly associated with complex crosstalk among different intracellular signaling. The effect of BDNF alone was inhibited only by the MEK inhibitor (U0126), whereas the effect of BDNF in combination with AS1949490 was reduced by the inhibitors of PI3-kinase (LY294001), phospholipase Cγ (U73122), and protein kinase C (bisindolylmaleimide I and Gö6983) as well as U0126. Thus, while the MEK-ERK pathway plays a fundamental role in the BDNF-induced upregulation of its own mRNA levels, BDNF was able to further activate the phospholipase Cγ and protein kinase C pathways in the presence of AS1949490, resulting in the increased Bdnf expression.
Activation of the protein kinase C pathway by inhibition of 5′-lipid phosphatase SHIP2 is an unexpected pharmacological event, because no such functional link has been reported in the peripheral insulintargeted tissues. The underlying mechanism remains unclear; however, increased PI(3,4,5)P 3 may be a key player, since PI(3,4,5)P 3 has been reported to cause activation and adequate translocation of phospholipase Cγ in blood cells (Gratacap et al., 1998; Bobe et al., 2001 ). In the presence of AS1949490, BDNF may readily activate the phospholipase Cγ by utilizing PI(3,4,5)P 3 , and indirectly activate protein kinase C through amplification of the diacylglycerol and/or inositol 1,4,5-trisphosphate/Ca 2+ levels. The fact that protein kinase C is directly activated by PI(3,4,5)P 3 (Nakanishi et al., 1993; Singh et al., 1993) raises another possibility that increased PI(3,4,5)P 3 by AS1949490 might promote BDNF-induced activation of protein kinase C. However, simple accumulation of PI(3,4,5)P 3 appears to be insufficient to strengthen the positive feedback mechanism of BDNF action, because VO-OHpic, an inhibitor of 3′-lipid phosphatase PTEN, failed to amplify the self-induced Bdnf expression. Indeed, changes in the balance between PI(3,4) P 2 , PI(4,5)P 2 , and PI(3,4,5)P 3 are known to strongly affect neural functions (Kam et al., 2016) . Therefore, SHIP2 may serve as a gatekeeper of the BDNF-phospholipase Cγ-protein kinase C signaling pathway to regulate the cytosolic levels of Bdnf exon IV-IX mRNA.
The protein kinase C-dependent mechanism for amplifying the selfinduced Bdnf mRNA in the presence of AS1949490 was independent of CREB-mediated transcription, because no influence of AS1949490 on the phosphorylation levels of CREB was observed. Rather, the present mRNA stability assays demonstrated that AS1949490 increased the stability of Bdnf mRNA via protein kinase C. It has been reported that Hu/ELAV-like proteins, such as HuB, HuC and HuD, are the best characterized neuronal RNA-binding proteins which bind to target mRNAs containing adenine-uridine-rich elements (AREs) and increase mRNA stability (Lee et al., 2015) . The Bdnf mRNA contains ARE sequences at 3′-untranslated region (Fukuchi and Tsuda, 2010) . The activation of protein kinase C has been reported to promote the binding of HuD and Bdnf mRNA, leading to its stabilization (Lim and Alkon, 2012) . Therefore, AS1949490 may promote the stabilization of Bdnf mRNA by indirectly activating the BDNF-protein kinase C pathway. In the brain of patients with Alzheimer's disease, decreased protein levels and reduced signaling activity of protein kinase C have been observed (Wang et al., 1994; Talman et al., 2016) . Administration of protein kinase C activator increased the BDNF protein levels in the hippocampal CA1 region in Alzheimer's disease transgenic mice (Hongpaisan et al., 2011) . We therefore anticipate that SHIP2 inhibition may be useful approach to restore the BDNF levels in the pathological state of Alzheimer's disease by the protein kinase C-dependent mechanism. The present MTT assay demonstrated that AS1949490 caused neuroprotective effects against Aβ neurotoxicity, but did not show any interaction with BDNF at the concentrations used for inducing the synergistic upregulation of Bdnf mRNA. Amyloid β has been reported to increase PI(3,4)P 2 and reduce PI(3,4,5)P 3 levels via recruitment of SHIP2 to plasma membrane in neurons, leading to cytotoxic events through activation of glycogen synthase kinase 3β (GSK3β) (Kam et al., 2016) . AS1949490 blocked these processes (Kam et al., 2016) . A higher concentration of BDNF can prevent Aβ-induced neuronal apoptosis via the PI3-kinase-PI(3,4,5)P 3 -Akt-GSK3β pathway (Kim, 2014) . The overlapping mechanisms between AS1949490 and BDNF may explain the reason of no enhancement of BDNF action by AS1949490 in our MTT results. Thus, among the actions of BDNF, the inhibition of SHIP2 appears to specifically enhance the self-amplification of BDNF.
The present behavioral analyses demonstrated that i.c.v. injection of AS1949490 induced the memory-improving and anti-depressant effects in passive avoidance test and forced swim test, respectively. BDNF is known to play crucial roles in behavioral performance. For example, in the passive avoidance test, BDNF delivered to the brain has been reported to improve cognitive function in mice with traumatic brain injury (Khalin et al., 2016) . In the forced swim test, administration of BDNF into the rat hippocampus caused an anti-depressant effect (Hing et al., 2018) . We also have reported that deltamethrin, a drug that can increase the expression of Bdnf mRNA, exhibited an anti-depressant effect in a BDNF-dependent manner (Takasaki et al., 2013) . Therefore, we anticipate that the behavioral changes by AS1949490 might be, at least partly, due to enhancement of the expression and actions of BDNF. To address the involvement of BDNF protein, activity-dependent production and/or release of BDNF at individual synapse levels need to be analyzed in vivo (Marosi and Mattson, 2014) . Since previous studies also have shown that AS1949490 improved higher brain functions in different animal models (Soeda et al., 2010; Kam et al., 2016) , further study with advanced technology is required to clarify the mechanism 6 . Effects of the SHIP2 inhibitor on behaviors related to memory, anxiety, and depression in mice. A-B) Effects of the SHIP2 inhibitors, AS1949490 and CPDA, in Y-maze test using C57BL/6J (10-11 weeks old; A) and HFD/STZ mice (16 weeks old; B). The test was conducted 1 h after i.c.v. injection of AS1949490 (AS, 0.03 μmol), CPDA (0.03 μmol), or vehicle (DMSO). Graphs show percent correct alteration to enter the different arms. n = 13-15 mice (A) and 11-13 mice per group (B). C-D) Effects of AS1949490 and CPDA in step-through passive avoidance test using C57BL/6J (10-11 weeks old; C) and HFD/STZ mice (16 weeks old; D). Mice were i.c.v. injected with AS1949490 (AS, 0.03 μmol), CPDA (0.03 μmol), or vehicle (DMSO) just after receiving a foot shock in the dark room on day 1, and retention of the passive avoidance memory was evaluated on day 2. Graphs show the latency to enter the dark room on day 1 (control session) and day 2 (memory test session). n = 10-13 mice (C) and 10-13 mice per group (D). E) No effect of AS1949490 in elevated-plus maze test using C57BL/6J (7-8 months old). AS1949490 (0.03 μmol) or vehicle (DMSO) was i.c.v. injected 1 h before the test. Values represent time spent in open arms on elevated plus maze during the 5-min observation. n = 10-15 mice per group. F) Improving effects of AS1949490 in forced swim test using C57BL/6J (7-8 months old). Mice were i.c.v. injected with AS1949490 (0.03 μmol) or vehicle (DMSO) once a day for 5 days. Graph shows immobility time on day 5 as an index of depressive-like behavior. n = 10-12 mice per group. Data were expressed as the mean ± S.E.M. ‡ P < 0.1, * P < 0.05, ** P < 0.01.
underlying its central actions more precisely.
In conclusion, the SHIP2 inhibitor AS1949490 caused beneficial effects on neural functions both in vitro and in vivo. In particular, our findings that AS1949490 increased the Bdnf mRNA expression provide novel insight into a SHIP2-targeted treatment of neurological diseases associated with insufficient BDNF functions, including Alzheimer's disease and major depression. However, AS1949490 shows relatively poor pharmacokinetics for prolonged clinical use (Suwa et al., 2010) . Therefore, future study is warranted to obtain more effective, centrallyacting SHIP2 inhibitors.
